Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients

Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)

The objective of the study is to examine whether the use of low-dose aspirin (75-100 mg / day) reduces the risk of cardiovascular disease in patients with chronic kidney disease (stage 3 or 4).

Hypothesis: The low-dose aspirin reduces cardiovascular risk in patients with chronic kidney disease without increasing the risk of bleeding

Inclusion Criteria:

• sign informed consent
• males 45-79 years or females 55-79 years. -Stage 3 or 4 CKD (estimated GFR by MDRD abbreviated, between 15 and 60 ml / min/1.73 m2) -

Exclusion Criteria:

• a previous cardiovascular event: cardiac arrhythmias, cardiac arrest, angina or acute myocardial infarction, stroke, carotid stenosis of more than 50%, peripheral vascular arteriopathy documented
• hospitalization for any cause in the last three months prior to inclusion in the study allergy of acetyl-salicylic acid
• coagulopathy from any cause
• thrombocytopenia <150,000 platelets
• liver disease from any cause
• Infection by hepatitis B virus, hepatitis C or HIV
• immunosuppressive treatment within 12 weeks before inclusion in the study
• Major bleeding events including gastrointestinal bleeding and brain hemorrhage.
• hemoglobinopathies (eg sickle cell disease or thalassemia of any kind)
• active malignancy (except non-melanoma skin cancer). May be included in the study patients with malignant neoplasia who have remained disease-free for at least the previous 5 years.
• uncontrolled inflammatory disease or symptomatic (eg rheumatoid arthritis, lupus, Chrom disease or bowel inflammatory disease)
• hemolysis
• treatment with oral anticoagulation and / or antiplatelet therapy prior.
• poorly controlled hypertension (> 160/90 mm Hg) -pregnancy or breast-
• women of childbearing potential not using effective contraception.